Login
Home / PRTC.L : LSE
Follow Compare
AI Analysis Fundamentals Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

PureTech Health plc

121.3p -$3.30 (-2.65%)
LSE · 16 Sep 2026 07:07 UTC
Previous Close
119.8p
Day Range
118p121.3p
Year Range
104.71p143.6p
Market Cap
295.27M
AVG Volume
603.05K
Trailing/Forward PE
-/-
PEG ratio
-
Dividend Yield
-
Next Earnings Date
2026-09-22
Primary Exchange
London Stock ExchangeUK
PureTech Health plc
PRTC.L
Stockpicker

Video analysis: PRTC.L

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PRTC.L

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

gurufocus.com · 9 Sep 2026

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
PureTech Health: Notice of Half-Yearly Results

gurufocus.com · 4 Sep 2026

PureTech Health: Notice of Half-Yearly Results

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended 30 June 2026 on Tu
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (

gurufocus.com · 25 Aug 2026

Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (

Celea Therapeutics, Inc. ("Celea" or the "Company"), a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

gurufocus.com · 25 Aug 2026

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

gurufocus.com · 2 Jul 2026

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tra

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.